Amgen Inc. (NASDAQ:AMGN) Shares Sold by KCM Investment Advisors LLC

KCM Investment Advisors LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,086 shares of the medical research company’s stock after selling 356 shares during the quarter. KCM Investment Advisors LLC’s holdings in Amgen were worth $23,741,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in Amgen during the 3rd quarter worth approximately $150,000. Texas Capital Bank Wealth Management Services Inc boosted its stake in shares of Amgen by 144.0% in the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 1,747 shares of the medical research company’s stock worth $563,000 after acquiring an additional 1,031 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of Amgen by 9.5% during the third quarter. Two Sigma Advisers LP now owns 784,900 shares of the medical research company’s stock worth $252,903,000 after purchasing an additional 68,000 shares in the last quarter. Wellington Management Group LLP raised its stake in Amgen by 2.1% in the 3rd quarter. Wellington Management Group LLP now owns 239,354 shares of the medical research company’s stock valued at $77,122,000 after purchasing an additional 4,942 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC raised its stake in Amgen by 38.0% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 93,668 shares of the medical research company’s stock valued at $30,181,000 after purchasing an additional 25,806 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. Company insiders own 0.69% of the company’s stock.

Amgen Trading Down 5.0 %

Shares of NASDAQ AMGN opened at $294.39 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a market capitalization of $158.15 billion, a PE ratio of 38.99, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a fifty day simple moving average of $304.18 and a 200-day simple moving average of $297.49.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.23%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AMGN. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 29th. UBS Group reissued a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $314.04.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.